A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia.Shi Yan,Hu Zhou, Ruibin Huang,Fang Wang,Heng Mei,Lie Lin,Jingming Guo,Xin Zhou,Zhenyu Li, Yaorong Liu, Sichen Li, Wei Zhou,Yu Hou,Ming HouAmerican journal of hematology（2024）引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
